BioSpace News Archive

Agreement opens reimbursement pathway for thousands of patients with migraine and cluster headache

Oryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that Executive Directors of the company will present at several reputed international conferences in January-February.

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to announce that, subject to regulatory approval, it has retained Independent Trading Group, Inc. (“ITG”) to provide market-making services to the Company (the ”Engagement”).

iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer

To the Detriment of the Sickle Cell Disease Community, the Draft Report Does Not Accurately Reflect or Interpret the Original Clinical Data and Related Efficacy and Safety of L-Glutamine Validated and Approved by the FDA

Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced positive proof-of-concept (POC) study results out to 12 weeks using its Rapid Acoustic Pulse (RAP) Device for the treatment of fibrotic (keloid and hypertrophic) scars.

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, introduces Evoke, a breakthrough non-invasive solution for facial remodeling.

Select Medical Holdings Corporation (“Select Medical”) (NYSE: SEM), today announced its business outlook for calendar year 2020.

HeartVista, a pioneer in AI-assisted MRI solutions, today announced that entrepreneur and industry veteran Mark Leslie has joined its Board of Directors. Leslie was the co-founder, Chairman and CEO of VERITAS Software.